CDI Co-Hosts Webinar with Epicured on Trends & Best Practices for Diagnosing & Treating Functional GI Disorders

The COVID-19 pandemic has played a major role in the medical field and has altered the lives of patients’ throughout the world. Commonwealth Diagnostics International (CDI) co-hosted Epicured’s Partners in Health November 2020 Clinical Webinar featuring a panel of Gastroenterology experts who explored trends and best practices for diagnosing and treating functional GI Disorders in a…

Working Towards a Cure: CDI Continues Partnership with Rome Foundation

Commonwealth Diagnostics International, Inc (CDI) has renewed their commitment to the Rome Foundation, an independent 501(c)3 organization whose mission is to improve the lives of people with functional GI disorders. The foundation provides support for activities geared towards data and educational information, which assists in the diagnosis and treatment of Disorders of Gut Brain Interactions. Millions of…

COVID-19 Response: CDI Commits to Continuity of Care for Functional GI Patients During Time of Uncertainty

A Letter from CDI President Craig Strasnick: Commonwealth Diagnostics International, Inc. (CDI) today announced its commitment to assist in the continuity of care for the millions of Gastrointestinal sufferers in the United States. The healthcare delivery system is being pushed to the brink of its capacity, and these times have brought with them a significantly…

CDI Introduces Validated At-Home Collection Kit for IBSchek®

The Improved Sample Collection Method Expands Access to the Blood Test for Diagnosing DiarrheaPredominant and Mixed-Type Irritable Bowel Syndrome SALEM, MA February 1, 2020 – Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek®, the first clinically validated biomarker blood test for…

CDI Announces Participation in Clinical Trial with the University of Michigan

Salem, MA – January 10, 2020 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to participate in a clinical trial with the University of Michigan, one of the largest gastroenterology practices in the country and a leader in the GI community. The clinical trial, Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea (IBS-D),…

CDI Announces Participation in the U.S Department of Veterans Affairs Community Care Network

Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the U.S. Department of Veterans Affairs’ (the VA’s) Community Care Network (CCN). The CCN is the VA’s direct link with specialized community providers, like CDI, to ensure that over 9 million enrolled Veterans receive adequate choice of and access to proper, timely, and…

CDI Announces Its Participation in the Blue Cross Blue Shield of Massachusetts Network

Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the Blue Cross Blue Shield of Massachusetts Network. CDI is a diagnostic laboratory located in Salem, Massachusetts that offers a variety of products, services, and technologies that aid in the diagnosis of gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and Irritable…

First Clinically Validated Blood Test for Diagnosing Diarrhea-Predominant and Mixed-Type Irritable Bowel Syndrome

Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek™, the first clinically validated blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M). CDI will officially re-launch IBSchek to the gastroenterology community at Digestive Disease Week in Washington, DC in June…

CDI Receives MDEL In Canada for Non-Invasive Diagnostic Breath Tests

Commonwealth Diagnostics International, Inc. (CDI), the leader in hydrogen and methane breath testing® for functional gastrointestinal disorders, announces its entry into the Canadian healthcare market. CDI will offer its state-of-the-art, non-invasive, functional GI diagnostic tests to the approximately five million Canadians afflicted with Irritable Bowel Syndrome (IBS)1, and millions of other patients suffering from functional…